One of the stocks to have emerged as a major gainer on Tuesday was that of Vitality Biopharma Inc (OTCMKTS:VBIO). The company, which is involved in developing therapies from CBD, announced yesterday that its product VBX 100 was awarded the coveted Orphan Drug Designation by the United States Food and Drug Administration.
It goes without saying that it was a major development for the company and the market recognised that as well. As investors piled on to the stock following the announcement the stock soared by as much as 28% and it is likely the that Vitality stock is going to remain on the radars of many investors this morning as well.
VBX 100 is a CBD based medicine that is meant for the treatment of patients who might be suffering from pediatric ulcerative colitis. Brandon Zipp, who is the Chief Science Officer at Vitality spoke about the development as well and called it a ‘significant milestone’ for the medicine development program that is in place at the company.
He went on to state that the company is now looking into further speeding up its research initiatives so that it can produce more products to take care of other conditions.
 Stock Soars 28%: What’s The Buzz?){kind=link}